Skip to main content
BioSyent Inc. logo

BioSyent Inc. — Investor Relations & Filings

Ticker · RX ISIN · CA0906901081 TSXV Manufacturing
Open in API
Filings indexed 411 across all filing types
Latest filing 2021-03-17 Management Reports
Country CA Canada
Listing TSXV RX

About BioSyent Inc.

https://www.biosyent.com/

BioSyent Inc. is a profitable, growth-oriented specialty pharmaceutical company focused on enhancing patient lives by addressing unmet medical needs. The company's primary business model involves sourcing, in-licensing, and acquiring innovative pharmaceutical and healthcare products globally for development and commercialization. BioSyent markets a diverse portfolio of products, including prescription, over-the-counter, and behind-the-counter options, primarily serving markets in Canada and select international regions.

Recent filings

Filing Released Lang Actions
Annual MD&A - English.pdf
Management Reports Classification · 100% confidence The document is titled 'BioSyent Inc. Management’s Discussion and Analysis' for the years ended December 31, 2020 and 2019. It contains detailed sections such as Introduction, Forward-Looking Statements, Accounting Estimates and Policies, Non-IFRS Financial Measures, Overview, Vision, Strategy, and Products, and detailed financial and operational discussions. The document references audited consolidated financial statements and discusses financial condition, results of operations, and management's perspective on performance and outlook. This matches the characteristics of a Management Discussion and Analysis (MD&A) report, which is a detailed explanation by management of financial results and business trends. The document length is substantial (15,000 characters), indicating it is the full report rather than a brief announcement. Therefore, the appropriate classification is Management Reports (MDA).
2021-03-17 English
Audited annual financial statements – English.pdf
Annual Report Classification · 100% confidence The document is titled 'Audited Consolidated Financial Statements for the years ended December 31, 2020 and 2019' and includes detailed financial statements such as the Consolidated Statements of Financial Position and Comprehensive Income. It contains management's responsibility statement, auditor's report, and notes to the financial statements. The document is approximately 15,000 characters long, indicating it is a full report rather than a brief announcement. The presence of an independent auditor's report and comprehensive financial data confirms this is the official annual financial report. Therefore, this document fits the definition of an Annual Report (10-K) filing type. FY 2020
2021-03-17 English
ON form 13-502F1 (class 1 and 3B reporting issuers - participation fee).pdf
Regulatory Filings Classification · 100% confidence The document is titled 'FORM 13-502F1 MANAGEMENT CERTIFICATION' and is a certification by an officer (VP Finance and CFO) of BioSyent Inc. It certifies the completeness and accuracy of information submitted to the Ontario Securities Commission under Rule 13-502 Fees. The content includes market value calculations of equity securities for specified trading periods and fee calculations. There are no financial statements, management discussion, or detailed financial results. The document is primarily an officer certification related to regulatory fee filings. According to the Certification Rule, such documents should be classified as Regulatory Filings (RNS) rather than as financial reports or other categories.
2021-03-17 English
AB form 13-501F1 (class 1 and 3B reporting issuers - participation fee).pdf
Regulatory Filings Classification · 95% confidence The document is a Management Certification related to Form 13-501F1, which is a regulatory form submitted to the Alberta Securities Commission. It includes certification by an officer (VP Finance and CFO) about the completeness and accuracy of the information provided, including market values and participation fees. The document does not contain financial statements or detailed financial analysis but is primarily a certification and regulatory submission. Therefore, it fits the category of Regulatory Filings (RNS) rather than a full financial report or other specific filing types.
2021-03-17 English
News release - English.pdf
Earnings Release Classification · 95% confidence The document is a press release dated March 17, 2021, announcing BioSyent Inc.'s financial results for the fourth quarter and full year ended December 31, 2020. It includes detailed financial highlights such as net revenues, EBITDA, net income, EPS, and shareholders' equity changes. It also references the availability of the company's audited consolidated financial statements and Management's Discussion and Analysis (MD&A) on SEDAR, but does not contain the full financial statements or MD&A itself. The document is approximately 8,321 characters long, which is relatively short for a full annual report but typical for an earnings release. The content focuses on key financial results and business highlights, consistent with an Earnings Release (ER). It is not a full Annual Report (10-K), Interim Report (IR), or Management Discussion and Analysis (MDA) document. Therefore, the appropriate classification is Earnings Release (ER). FY 2020
2021-03-17 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release announcing the scheduled date for BioSyent Inc.'s Q4 and full year 2020 earnings release. It states the company will report financial results on March 17, 2021, and mentions a presentation will be available on the same date. The document itself does not contain any financial results or substantive financial data, only an announcement of the upcoming earnings release. According to the 'MENU VS MEAL' rule, such announcements are classified as Earnings Release (ER) if they contain key highlights, but this document only announces the date and availability of the report, not the results themselves. Therefore, it is best classified as a Regulatory Filing (RNS) since it is a general regulatory announcement about the timing of the earnings release, not the earnings release itself.
2021-03-11 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.